B2B ad examples

Implantoloog? Bij Tandartsenpraktijk Epe krijg je tot 45% van de omzet en ben je de medisch regisseur voor implantologie. Je plaatst implantaten, doet botopbouw en sinusliften, en de behandelkeuzes op jouw vakgebied liggen bij jou. Je neemt een goed gesaneerde agenda over in een moderne, lichte praktijk in het centrum van Epe. ✓ Tot 45% van de omzet, afhankelijk van opleiding en ervaring ✓ Dagen en werktijden in overleg ✓ OPG, microscoop en CEREC PrimeMill met scanner ✓ Ruimte om door te groeien in endodontie of chirurgie Bekijk de vacature.

Tandarts in Twello, voor 8 tot 16 uur per week? Bij Tandartspraktijk de Gelder werk je op één of over twee behandelkamers. Je werkt zelfstandig en bouwt je eigen patiëntenbestand op, in een praktijk met veel vaste patiënten: van ouderen met complexe zorgvragen tot jonge gezinnen. Je start als zzp'er, met uitzicht op een langdurige samenwerking of een vast dienstverband. ✓ 8 tot 16 uur per week, donderdag vast ✓ 4 goed uitgeruste behandelkamers ✓ Geschikt vanaf 1 tot 2 jaar werkervaring ✓ Een stabiel team, met een praktijkleider voor begeleiding Bekijk de vacature.

Bouw jij graag aan platforms die er écht toe doen? Bij het Antoni van Leeuwenhoek werk je aan Azure, Kubernetes en Data & AI-platformen. Samen met data engineers en AI-specialisten zorg je voor een omgeving waarop innovatie kan draaien.

When a batch record doesn’t match how a product is made, operators add notes and QA follows up on each one. CaliberBRM lets you configure reusable templates around each product and process. Pharma manufacturers in 16+ countries already work with Caliber. Explore how templates are set up in CaliberBRM.

Notable Patent Structures are now live in Drug Hunter's Curated Patents feed! Who has time to open every new patent filing each week? Now, the Curated Patents feed allows you to quickly scan each week’s notable new patent filings to stay current on what the industry is working on. You can now: • 𝗦𝗰𝗮𝗻 𝗻𝗲𝘄 𝗿𝗲𝗹𝗲𝗮𝘀𝗲𝘀 𝗯𝘆 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲. See example structures alongside company, target, relevant therapeutic area, and individual patent data annotations. • 𝗦𝗸𝗶𝗽 𝗠𝗮𝗿𝗸𝘂𝘀𝗵 𝗲𝘆𝗲𝘀𝗼𝗿𝗲𝘀. See specific example compounds validated by Ph.D. scientists to get a quick sense of the chemical matter. • 𝗦𝘁𝗮𝘆 𝗰𝘂𝗿𝗿𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗯𝗿𝗼𝗮𝗱𝗲𝗿 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆. We triage filings so that you can tune out the noise and quickly understand disclosures from across the industry outside of your main focus area. • 𝗚𝗼 𝗱𝗲𝗲𝗽𝗲𝗿 𝘄𝗶𝘁𝗵 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗲 𝗦𝗲𝗮𝗿𝗰𝗵. Copy/paste any SMILES into Molecule Search and edit it to find related clinical compounds, FDA approvals, and disclosures. Already a Drug Hunter member? Log in and navigate to Patents! Think this tool would help your team? Read more about Drug Hunter’s Curated Patents here: https://lnkd.in/eSNWZv_2/?utm_campaign=Boost_Post_BrandAwareness_Oct16,2026&utm_source=linkedin&utm_medium=paid&utm_id=1231927616&hsa_acc=510103803&hsa_cam=1231927616&hsa_grp=914217416&hsa_ad=1647267766&hsa_net=linkedin&hsa_ver=3 #DrugDiscovery

$24,666 raised (and counting). Hundreds showing up. One cause that matters. Last Friday and Saturday, coinciding with World Mental Health Day, Aurora Healthcare teams, families and communities came together across Australia for Move For More, raising funds for Suicide Prevention Australia. For many across our Aurora community, it meant giving up part of their weekend to stand alongside colleagues, friends and neighbours for a cause that matters deeply. And that commitment speaks volumes. This Mental Health Month, Mental Health Australia's theme Together We Thrive reminds us of the power of connection, community and belonging. Beyond the fundraising, we're proud of the conversations started, the connections strengthened and the genuine care shown by our Aurora community. But we're not stopping at $24,666! Every additional donation helps support the vital work of Suicide Prevention Australia, and we want to see just how much more we can achieve together. Help us push our fundraising total even higher. Donate, share our campaign and encourage others to get behind Move For More. Let's see what more we can achieve together! 👉 https://lnkd.in/gBBp9ghd With thanks to our major donating sponsors Medibank Group, Bidfood Australia Ltd, Slade Pharmacy.

Investigating a discrepancy on paper means going back through the batch record page by page. CaliberBRM logs every activity with the operator’s name and a timestamp, so the full batch history is in one place. Caliber has been building software for pharma manufacturers since 2001. See how CaliberBRM tracks each step of a batch.

Front-door calls, referrals, and documentation, run on one platform. Join Coffee with Commure on Oct 29, 11:30 AM to 12:15 PM ET.

#PRESS #AscendisPharma is pleased to announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of our treatment for children with #achondroplasia two years of age and older whose epiphyses are not closed. The European Commission will consider the CHMP recommendation, with a final decision expected by the end of this year. Learn more: https://lnkd.in/gF4_7gm8

Claimable helps pharma teams automate patient appeals, reduce abandonment, and get more patients on prescribed therapy.

Passende hulpmiddelen maken het werk voor zorgmedewerkers makkelijker en ondersteunen goede zorg. Met de hulpmiddelenscan krijg je inzicht in de behoefte op de werkvloer en zie je of je huidige hulpmiddelenbestand daar nog goed op aansluit.

Oncology drug development has a difficult mandate: move promising therapies forward faster while maintaining rigorous standards for safety and clinical benefit. The challenge is substantial. An estimated 3.4% of oncology drug candidates entering clinical development ultimately reach approval, among the lowest success rates across therapeutic areas [1]. More efficient development strategies can help improve how promising therapies are identified and evaluated. In a meta-analysis of 570 phase II oncology trials, biomarker-guided approaches were associated with response rates of 31%, compared with 10.5% for non-personalized strategies [2]. Adaptive trial designs and master protocols, including basket, umbrella and platform trials, can allow researchers to evaluate multiple hypotheses more efficiently and adapt studies as evidence emerges [3,4,6]. Expedited regulatory programs and earlier interaction with regulators can help address development questions sooner [5]. AI and advanced computational approaches are also being explored across trial design, patient selection, recruitment, and data analysis [7]. These approaches are not about weakening the evidentiary standard, but about reducing avoidable delays, improving decision-making and concentrating resources on therapies with the strongest potential to benefit patients. Faster oncology development means generating the right evidence more efficiently and delivering meaningful innovation to patients sooner. #Oncology #CancerResearch #PrecisionOncology #TranslationalMedicine #PersonalizedMedicine #MedicalInnovation #FutureOfMedicine #Biotechnology

In this episode of the Talking Health and Wellbeing Podcast, we are joined by Dan Kane, Forensic Examiner and Obstetrician/Gynaecologist, and Catherine Marsh, Forensic Nurse Examiner and Clinical Innovation Project Coordinator, to discuss the care and support available following sexual assault. The conversation explores the role of Sexual Assault Treatment Units (SATUs), what people can expect when attending a service and how trauma-informed approaches help ensure compassionate, person-centred care. Dan and Catherine discuss the importance of creating safe and supportive environments, the multidisciplinary nature of SATU services and the range of healthcare, forensic and support options available to those who attend. The episode provides valuable insight for both the public and healthcare professionals, highlighting the importance of awareness, understanding and access to specialist services following sexual assault. Listen on Spotify: https://bit.ly/4jH7yHF

Heb je binnen jouw zorgorganisatie voldoende zicht op welke hulpmiddelen aanwezig zijn, hoe ze worden ingezet en of ze nog aansluiten op de huidige zorgvraag? Met de hulpmiddelenscan van HartingBank krijg je inzicht in je hulpmiddelenbestand en waar kansen liggen om hulpmiddelen slimmer in te zetten. Zo maak je onderbouwde keuzes over inzet, beheer, onderhoud en vervanging.

Some moments stay with you. For Insa Gathmann, it was seeing early data in the late 1990s that suggested something unprecedented was happening. At first, it felt almost too good to be true. Nearly three decades later, as she proudly retires from Novartis after an extraordinary 30+ year career, the lead biostatistician looks back on a targeted therapy that helped transform chronic myeloid leukemia treatment and redefine what was possible for many patients living with the disease. Explore more: https://lnkd.in/gStgyTYH #30YearsofNovartis #Reimaginingmedicinetogether

Most companies ask what a membership costs. The better question: what is it worth? Here's the fee and what you get. Judge for yourself. We are a non-profit founded in 2019 and supported by the Novo Nordisk Foundation and the Danish Industry Foundation. The Hub exists to help health tech companies reach the healthcare providers and patients who actually need their solutions. 100+ companies are already benefiting. Fill out the form, and let's find out how we can help you too.

🎗️ What drives progress in liver cancer care? 📢 Not just one innovation. Not just one treatment. Not just one specialist. According to Prof. Maxime Ronot, some of the greatest advances in recent years have come from combining different treatment approaches and bringing experts together around the same patient. 💡 Because when expertise is shared and treatments are coordinated, patients can benefit from more tailored care and better outcomes. 🎥 Episode 2️⃣ of our Liver Cancer Awareness Month series explores why collaboration remains at the heart of modern liver cancer management. #Guerbet #LiverCancerAwarenessMonth #LiverCancer #CancerCare #PatientCare #Radiology #HealthcareInnovation

At our Carer Industry Forum 26, more than 220 senior leaders came together to reflect on the progress made since Forum 25 — from relationships forged and collective leadership to collaboration in action. Over seven months, our organisations have worked together on 15 carer support initiatives to improve awareness of carers across the health sector and connect them with support when they need it. Some pilots are now in their second or third iteration as we build on what works and look to expand their impact. At the heart of this work is recognising the critical role carers play in supporting the health and wellbeing of care recipients. Jane Rowan of Eating Disorders Families Australia (EDFA), put it powerfully: “Caring for the carer is not negotiable. If we want the people they care for to have quality of life and to recover where possible, carers are the essential core ingredient to that.” Read more about Carer Industry Forum 26: https://lnkd.in/gbGnhcwX

Wil jij als POH-S echt iets betekenen voor patiënten? Begeleid mensen met chronische aandoeningen en werk nauw samen met de huisarts. Bekijk de vacatures in regio Eemland.

Get the latest jobs and industry news

Get the latest jobs and industry news

Severe tricuspid regurgitation now has multiple approved interventional therapies. See how Dr. Marianna Adamo and Dr. Elisa Pezzola of the University of Brescia choose the optimal treatment for this patient in a newly published EBAC-accredited case study! Learn more with expert commentary from Dr. Matti Adam: https://lnkd.in/djy5jGgp * *This link leads to a third-party website not controlled by Edwards Lifesciences. Edwards Lifesciences does not have editorial control for the content of the presentations. Expert opinions, advice and all other information expressed represent contributor’s views and not necessarily those of Edwards Lifesciences. EBAC = European Board for Accreditation of Continuing Education for Health Professionals.

The latest report details the management of severe mitral regurgitation and torrential tricuspid regurgitation in a 71-year-old patient with a complex cardiovascular history. Learn how Dr. Stefan Toggweiler managed this patient with multiple valvular disease in this EBAC-accredited case study with expert commentary from Prof. Amin Polzin: https://lnkd.in/dEuvMXmJ * *This link leads to a third-party website not controlled by Edwards Lifesciences. Edwards Lifesciences does not have editorial control for the content of the presentations. Expert opinions, advice and all other information expressed represent contributor’s views and not necessarily those of Edwards Lifesciences. EBAC = European Board for Accreditation of Continuing Education for Health Professionals.

When clinical conditions change quickly, decisions must be made with confidence. Cardiohelp II supports informed clinical decision-making through continuous monitoring, clear trend visibility, and integrated NIRS to help assess tissue oxygenation in real time. Supporting confident and informed decisions in time critical situations. Learn more about Cardiohelp II: https://lnkd.in/dQstXmNh